Beihai Biotech is an innovative biopharmaceutical company guided by the principle of "Putting Patients First, Innovation for All." We focus on various disease areas, including oncology and pain management, with a special emphasis on developing groundbreaking oncology drugs to address significant unmet clinical needs. With a global perspective, the company possesses two pioneering global drug technology platforms, demonstrating sustained innovative research and development capabilities.We have strategically planned over 10 differentiated innovative drug development pipelines and obtained more than 30 authorized invention patents in China, the United States, the European Union, and other regions, committed to pioneering innovation in drug development.

  Currently, Beihai Biotech has obtained nine clinical trial permits (IND) in China and the United States, with several new drug projects entering critical phases of clinical trials and NDA submissions.

  Beihai Biotech adheres to the motto "Reviving with Scientific Innovation", with original innovation as its core driving force. We continuously develop clinically urgent, safe, and effective breakthrough therapeutic drugs to provide better treatment options for patients worldwide. With an unwavering commitment to "Pursuing Excellence, Unwavering Persistence" we steadfastly champion patient well-being, ensuring a healthy future.